tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascletis Pharma Secures FDA Clearance for Psoriasis Drug Trial

Story Highlights
Ascletis Pharma Secures FDA Clearance for Psoriasis Drug Trial

Elevate Your Investing Strategy:

The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).

Ascletis Pharma Inc. has announced that the U.S. FDA has cleared its IND application for ASC50, an oral small molecule IL-17 inhibitor, for a Phase I trial targeting mild-to-moderate plaque psoriasis. ASC50 has shown promising preclinical results, including higher drug exposure and strong efficacy, positioning it as a potential best-in-class treatment. The Phase I trial is set to begin in the third quarter of 2025, marking a significant step in Ascletis’s development pipeline.

The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on discovering and developing innovative drugs for the treatment of autoimmune and inflammatory diseases. The company specializes in oral small molecule inhibitors, with a market focus on conditions such as psoriasis.

Average Trading Volume: 7,167,514

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.11B

Learn more about 1672 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1